7. A potential new drug target for colorectal cancer Challenge: 3D tumour mapping Using their novel 3D mapping technology, the Rosetta team identifies the antiporter SLC7A5 as a target for KRAS-driven colorectal cancer, opening new avenues for treating the disease. |